Search

Displaying all 5 results
DrugBest match

Pomalidomide

go.drugbank.com/drugs/DB08910
ApprovedInvestigational

Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

  1. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide

  2. Drug

    Isatuximab

    go.drugbank.com/drugs/DB14811
    ApprovedInvestigational

    Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and tw...

  3. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    It has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone

  4. Drug

    Iberdomide

    go.drugbank.com/drugs/DB12101
    ApprovedInvestigational

    [L64055] Iberdomide has shown anti-tumor activity in multiple myeloma cells resistant to lenalidomide and pomalidomide, and as a CELMoD is designed to degrade Ikaros and Aiolos more potently than immunomodulatory